SPC :
CAPIBINE F.C.TAB 150MG/TAB BTx60 BLISTER PVC/PE/PVDC/AL
ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ
1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ
Capibine
2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ
!"#
$%&
!"#
$%&
'("% )*#*+$" )",-
3. ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ
.
/
#"01"+1,"+%3%45
%1" 6# & "))%7mmx8
mm
mg/1111
#"01&"+1(%+1#(1 9&:"%
3%45%1" 6# & "))%
;mmx<mm
4. ΚΛΙΝΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ
4.1 Θεραπευτικές ενδείξεις
=)%"(!"!0
"#&">>>? @ABCD %
#"")((?$" )",D
=)%!"2
"!2"?$" )",D
=*&!""0%&)"11(&
"#*"%1)"2"1#(1
$E1%?$" )",D
=13%?$" )",D
)%!"!0 "#*"%1(
1"2#&
"3(&#%1!"&F"%)21%!"!
"1" 1$!"%
=%&*&!"!&
"#*"%1(1"2
#&30(#%!"2#(1&"#
!"%+(!&&&
""*!"!"%
4.2 ∆οσολογία και τρόπος χορήγησης
="))",1&
)"2&+#1"%#"(%0
,"10"G*H "(
"2!%% % ""02%&
!"&)&&!&F)*)(!"
"%"%!31%&(%(
3%I)1%&%!1%&1*1%&
)&21,*%, 01&)&&
"3%&*JK
J
K
J
"#
&&J+#
L)
H01%)?$" )",D/
M!"
"&#&"+"!&12
N#"%)*&1!"+%01%"#(%%&
$%&%"(!""#&
"+%!"12"!2"(
"#*"%1(12"12
JK
J
#"%)21%2,"&%1"%*&?"*
$" +211JK
J
(%1"(%D)7
%1"&!21%;(1"%"(&F"(
!"!&1"#&">>>
)-1(&
O"12
"&#&"+"!&)"&"&
J
H%!"12+%01%%"3%&%&
$%&!"1*!<PK
J
#"%)J,"&%1"%*&)71"&!21%
;(1"%"(&+(-JK
J
2,"&%1"%*&
#"%)"0&?$" )",D'1
1" %+%01%%"3%&<K
J
#"%)2,"&%1"%*&)7%1"&!21%
;(1"%"(&1%1" %JK
J
%%1"F)*)(QRSA#(112
#"%%%"3%&%&$%&H&
!&1$ 1$%&
%&+!"#"%)"%#"()%%
%&+)*)()%("%%"2& *%&
1(&" %&21,*1%"%9%*
#"%"0"G&%&%&F#"()%%
"%)21%&)*)(&11 +21,*1%"%9%
*#"%"0"G&%&3&+
&!&1$ 1
$%&3&F1%"*1(!"
!&1"!">>>
)-1(&
"&12
H113%+%01%"#(%%&
$%&)%!"12"
12JK
J
2,"&%1"%*&)7%1"&
!21%;(1"%"(&+11;
K
J
3%#"%)21%1,$)#% "&
0"& !T$1 &U"%)21%,"1()*)(1
1&""&*&%31!E%+
21,*1%"%9%#"%"0"G&%&
3%&"3 "%#"()%%
3%&!&1$ 1
$%&3%&
V)1&*
U&/V)1&%&%!1%&1*1%&%&
21,*1%, 01&1%"3%&
$%&JK
J
.%&JK
J
?2,"&%1"%*&D
U("%&
%J
K
J
W"!1&
*
K(
#"()%%
M*1%
%?;XD
8K
J
M*1%
%?XD
-JK
J
T
? !
#"()%%
"
)"*
$" D
.,
01&?
JD
Y%
#"()%%
?D
Y%
#"()%%
?D
Y%
#"()%%
?D
ZJ- P T <
J;PT< - T T <
T8PJ < J T 7 8
TP-- J P 7
-;P;< J 7 -
;8P8J JT J 7 <
8TPJ- J P 8 T
J;PJ< J- J T
[J8 J< J J 7
U&J/V)1&%&%!1%&1*1%&%&
21,* % , 01& % "3%&
$%&K
J
. %&K
J
?2,"&%1"%*&D
U("%&
%
K
J
W"!&
*
K(
#"()%%
? !#"()%%
"
)"*
$" D
M*1%
%?;XD
;K
J
M*1%
%?XD
K
J
.,
01&?
J
D
Y%
#"()%
%?D
Y%
#"()%%
?D
Y%
#"()%%
?D
ZJ- J < -
J;PT< T J J -
7
T8PJ 7 T J ;
TP-- - 7 J J <
-;P;< ; J T <
;8P8J < J T 7 8
8TPJ- J P 7
J;PJ< J 7 -
[J8 JT J 7 ;
U""1)&)& % "%&)*)(&/
'
F3%,%#"()%%%&$%&
1"1*!11*1()*)(K(
"%%%&%&?(%&)*)(&( *%%&
%&DW%)1(!*!%01%%+
!"3%!")"'&3%&&
!*"!!" )")$"&(
%&)%E*(+#*+*%)2%&+
1$&*#0+%!"()*)(1"#
%%#*"&1*%((I!&
1$ $%!"%1"0)%
)% 1%&(&%&)*)(& 1,1"(
$"(3%L&%&$%&&
"))&3%&!I
01&"(&%&%&))&3%&
3(&/
U&T/H#(1M*%&L%&$%&?2&TP
$1 *( %!"D
Βαθμοί
τοξικότητας*
Μεταβολές δόσης κατά
τη διάρκεια ενός
θεραπευτικού κύκλου
Προσαρμογή δοσολογίας για
τον επόμενο
κύκλο / δόση (% δόσης
έναρξης)
\]!1& Y%"(%&
%&
Y%"(%&%&
\]!1&J
P
%
1, % Y91#"*%
$!123%&
X
PJ
%
1, % ;X
]!1PPT
%
1, % X
P7
%
1, %
Y9%)*)(
"
Y,"1E
\]!1&T
P
%
1, % Y9#"*%
$!123%&
]!1P
;X
PJ
%
1, % X
PT
%
1, %
Y9%)*)(
"
Y,"1E
\]!1&7
P
%
1, % Y9"
(
. )"&!*"
"&,&
!2&#+
(#"*%
$!123%&P
X
PJ
%
1, %
Y9%)*)(
"
Y,"1E
^H21,*1NationalCancerInstituteofCanadaClinicalTrialGroup
?NCICCTGD"("H(!&=3%&?%D("("
H(!&I")&)W!21%&.")&?_`aD
U")" 11&.1%%&%&O"&"+bc
defgRhiCeeAe+%7'2"1#"&P
&%"#"!"1+$" )",77
W1)
/W!&1"!1",*j+k
8
Kl
K("!1!"1$ "*jm
8
Kl!"
1$ )*)(1$%. 1%")"111&
")%"&3)(& % "&2
!"&3"!1&",*1*! *
+n
8
Kl("!1&1*1*! **;n
8
Kl+%!"1$%!"
="(&%&%&)*3%&%$%
#"%1*&2&)*)(&TP$1 *11
,"1 "G/
I"(&%&%&)*3%&%
$%#"%1*&2&)*)(&TP$1 *
11 ,"1 "G!")
21,*1" *T)%$%
21,*1%#%"%9%*#"%"0
"G&?*D ?*D,"1?D0"G?&D*
H%"#(&!"22+
!"%%%&!"&)%$%)
-
?D,"1?D"G+%#"()%%%&%&
!"&!"!"1#"&%"2
"o!&"3%&**,"10
"G*
% "&!"22)&3%&
&!*"21%#E1&1%$%
!" )"+%$%!"#%
% ,"12"G&""1
21,*1&#&))",&%","&
. ?D ?D,"1?D"G?D"
211+%!"1$%1"
3"#E%"2"o!&"3%&%&
$%&
F2%(,"1E&&3&&
&2&%!12&
="(&%&%&)*3%&%$%
#"%1 11 ,"1
"G
I"(&%&%&)*3%&%
$%#"%1 11
,"1 "G!")21,*1
" *T)%$%21,*1%
#%"%9%*#"%"0"G&?*D
?*D,"12?0D"G&?*D
U""1)&)&)2&%!12&/
F(")
L!1"(1, &
1%&!&1%( "+0
!2 &""1)(&%&%&L "#
!1&%","&)%( "%,
""*%(%
p,"(")
F$%!&1$"(,"(
")? !"%"%&1""%*TgK
q fRBRhfresAget"%"3%%&)*)(&DF
#%1, %&!21%*")0$!12T(7
!&11","(")? !"%"%&
TPgK"%"3%%&)*)(&D3
)" 1%!1H 1*%%&
;X)"#(%JK
J
!&11","(
")"%"3%%&)*)(&H!&11"
,"(")"%"3%%&)*)(&+
;
1*%%&)%"3%&K
J
H
!&1(,"(")? !"%"%&P
<gK"%"3%%&)*)(&D ""1)(
%&"#(&%&H "("2!%%
)"%(%&)*)(& !(&231
!21%%")$!12J+T(7 % "%&
)*)(&!%""1)(%&*&2
" *T. %)1% !"%
"%&1*! % "%&!"&1( *
TgK+Capibine!"W&
&""1)(&%&),"(")#2
%1!"%#"(%!"&12
?$%&" )",4F*15" *D
F*1/
L""1)(%&%&"3%&+ % "
1!"&1$%u+!21%&")&
$!12T(7#E1&1%)*)((#"&
!&%&[-0)" 1"&!&
N%$%#"%1(!%11
,"1 "G%*1&!&?[-0D+
%0!%""&!21%&")&$!12T(
7+1"1$1*0%)2(+
2)"%1"&!&H "(
"2!%%*!0%&[-0
P
H113%
/"%"(!%13%1%
#%1, %&#E1*1%)*)(!21%*
")0$!12T(7$"0#E1*1%)*)(
!21%*")0!&-0(1)2"&?$
" )",D'!&-0(1)2"&+
1*%%&%&"3%&%&$%&;X?8K
J
2,"&%1"%*&D. "%"3%
!&%&[-01$ )*)(11*1%
%"3%&$%&113%+%
%%&$%&1"1*!"
JK
J
2,"&%1"%*&
U"&%!1&
L "##(#"(%%&$%&"
%!1"#&"+"!2+
)"2"12
="&#"()%%&
="1E1"1
T 1 )21
4.3 Αντενδείξεις
<
\>"$"0"1*" *%!"1
,!""1%+
\V"!%%$%+( #
,"%" )",-+(%,!""%+
\H!&1)*(9%""1(&
o") %&?@v@D?$" )",77D+
\ % "%&2%%&%&)#&+
\H!&1$"(+"(
!"1$+
\H!&1$"(%( "+
\H!&1$"(,"( "? !"%
"%& *TgKD+
\O"1CfhQAw(1# #%1 )*&%
hQAw?$" )",7D+
\. "#3&1(
,"1 "G#"%)2#(112+
,"1 "G!"
#"%12
4.4 Ειδικές προειδοποιήσεις και προφυλάξεις κατά τη
χρήση
F3%""E%%
"1$ ""+
)&++12"1#"&P
&?"1("%#"&P&+1P1
"!"!%DI""&!21%&")&
"91&211%(%&
!"&+"1"%!" 9%(1*%
*
L ""
/W!&1$"( ""!"
"!2" 1$ )"
("*%%"0,0M"2
#"%1%!2(!&""G&)*)&?#
"1%DF ""$!12J21,*1"("
(!&3%& diCTC"E*&123%%%&
3%&*7P-0*K%1"("00*+%
""$!12T*&123%%%& 3%&*;P8
0*K%1"(" "",%%F ""
$!127123%%%& 3%&*x0*K%1"(
1%"( ""(% )%""(&("3%&
F1*%%&%&!","1E
"%?$" )",7JD
8
W, *%
/F, *%!""1$ (
1*E1%"0%%&1, %W!&1
"3+1++1( ""1")"()"
,*!2F, *%1""3,"(
"+"!&1"o "#%"1%
,"(")(%$%#"%))#"*&
1)* ,"3 , "1F3,"( "
"!(& %, *%+1"%
!%,"&. 1,, *%$!12J?(
1)2"D+%)*)(1$%!"
1%, *%1*EF)*)(!
"#"%)1#"&!(&
*!1#"&1*()#!
(#21&)&" )&I
,"1E1&"(&%&%&!"
,"1E)%#21%!21%%")
"%?$" )",7JD
H2"1#"&P&
?ywPrffeCzwhfD?)*%&
*&"1("%#"&P&(1P1
"!"!%("2!%1* "*"
#%1!"D=2"1#"&P&$!12"E*&
121+!%K"!%+1"1%%+0
"(31("2!%1*#"0K(0K(#%
%" E&"%"%&%&!%1"(&E*(&=
2"1#"&P&$!12J"E*&0"2!%1
"(31*#"0K(0K(##*&
1%1!2&")(
&"%"%&%&!%1"(&E*(&=2"1
#"&P&$!12T"E*&%+3*%+
,2&&&*#"0K(0K(
%# !(")(
&"%"%&%&!%1"(&E*(&.
1,2"1#"&P&$!12J(T+%#"()%%%&
$%&!"1#"#0"%%&(1*%&
$!12$"%&M %1, %"1
#"&P&$!12T+1&&%&$%&!
"1*!2N%$%%%
#"%121+ %#"()%%%&
$1%&]-?"3%D)1*1(("2
",()*)("1#"&P&+3&
%11*,"01"10%
1%%&%&V "# &3&
%3!%1()%",23%
2"1#"&P&!&)*)(1Capibine
"3%/
%!"1,!""1%#
#1"3%+1"1$1*
1," )1&1"+%! )#%&+""!10+
")2&+,! %"")",0
0*?1"1$1*2)*"0
1(%&{_DW&!21%&")&1"
#&!&1"%)21",&
"%"(&6#,"!"&""!1&
?1"1$1*(&1"1")(&+(&
#"&%"+$""&D+%! )#%+
1,")11"+"( "
1" !!& 1$$%
.$ 1) %"#(!&1"%10
"0%1 *+""!10%! )#%&?$" )",
7<D
VP("$1/
#,"!fP(
"$1 % ")*)(&1$%
W1) %"#(!&1"o "#P(
"$1?$" )",7<D
p&"2(U","2"2(1&/
"#(!&1"2(
","2"2(1&+#1 %), (
" !?$" )",7<D
H#"0%&$(%&("#&%"0/
"#(!&1#"0%$(%("#&
%"0+!0&&1"*!2 %
"%&)*)(&1$%
W% 1"22/
11%,"1(&
%"%&1#"()%%, 3%&$","%&+("3
1%1(23%%%&1%&1(&%&`b?|;XD%&cP
}hrhW 121
%"%+!0&)*1&(&E12
(1&#"01&v7J8%$%
H!&1$ #"!"$%&
1&#"%)21%!"1%
1"22!""! %
"(&%?id~(#"&"!"1$%&D
""1E#%%%2?$
" )",7D
F(")/
1*, &
1%&!&1%( "+%#"(%
%&$%&""!"
!&1(*&1"%(")+3"(*&
1, %&(&%01 *F#"()%%%&
$%&!"1,2
#E1&1%)*)(3(&%&#"!"%&xT+nbld
(#E1&1%)*)(3(&*%0
1","0?`l_+`c_DxJ+nbldF)*)(1
1!"$%&1"#"%)%!%
#"!"%1*!ZT+nbld(%&
1"," &1*!2ZJ+nbld
p,"(")/
%#%1, %&!21%*
")0$!12T(7!&11","( "
? !"%"%&TPgKD3%1%)" 1
%!1?$" )",&7J7TD
69%,") %&%&o""1%&?@v@D/
H +1%
11%+$"(3%?#1+ ""+
""3%D#E1%1P•b#
!9%"%&%&" %&%&@v@
H0&+1#%1321*1**@v@
3%1*+!0&!%,"*30" *%&P•b+
1"!W!&1)*(9%@v@
!"1$ !"1$%?$" )",
7TDH!&11%)*"1%9%@v@$
!"1$%+1"2%*!2%&
)%E*(3%&%0*&3")
?$" )",78DH%"*%$!12JP73&
3%&+%!""1*&*&
#*"(%"%"21%3%O"3 E
11%(1$ %%(3)%%%&"3%&+%&
"&%&$"%&*"%"21*3(*
I,!1)&&
/I!&!"
"!2" ),!1)&&+
*&""#&"2&+
#"%)21",!10"#0F!"
)&,!1&"#&!"3 +*&
"1E
H$"&"1&" &
/=1" )
$"&"1&" &*&2"1ceQCP
€fyCf%_f3(."1(p"%=!
"" !&%01
$"("1("% % "%&!"&
4.5 Αλληλεπιδράσεις με άλλα φαρμακευτικά προϊόντα και
άλλες μορφές αλληλεπίδρασης
M&%" *#")1%!1
(&
J
W%"%1 ,"1 "G/
V"01#"01&•P7J8/.&%
$","%+#3#!%1&1&,"10
%" *132%&$%& *
"*1 *‚vJ8>"%"#(!"
%$%)#"%)1"01J8
?#+,ƒ%D]%&%%"%1%
1"22" *+%" )",77
W% 1"22/
#,"!"#&
*"1"*(3%&K(1"")!&
1$$%#"1% 1"2
2*&%$","%%,"1%W&")&
1,%11"&1"&1#"1"2&1(&
1 %"3%%&!"&1$%1"&
"0&+11(1 %(%&
$%&H1(,"1%(1%
%"%&+, 3%&$","%&J+%
!"1$%23%1$%&"#(& *
%12%)"*%&P#"?`bD%&cP}hrh
;X1123%%%&1(&id~ 8X!0&
1$1&%&~P}hrh%" %+
12%$%""!1E
E1J8+ #"%E1WJ
TW7I!&1$ % 1"22
#"1$%""!2
))&*"1"*(3%&?v_(id~D
""1E#%%%2&
:ƒ%/
#,"!3%1&)"0&
,ƒ%& 1 % "#"%&#"(%&
$%&1,ƒ%+&11*1
" #*&1101%%%"%&
,ƒ%I!&1$ ,ƒ%#"1
$%!""!2 )%
"*%3%1*)"0*,ƒ%& 1
:32K:32/
11%121
$%,323,32
#1E"%%,"1%(%&$%&
*1$0u+,32#"%
%,"11(%&$%&%3%%&
1"#!,32/%1)%(%
?„_@D%&$%&1!"#"%10&
#(1TK
J
%%1"01J
K
J
%%1"%$%E1,
32?T1&DF#1%3%1"
T
#E1%)1 $%P•bKl…
#(11$%.#%&#E1
1%"01,23&) ",23&+
3&%&1%&132,23&,2
3&
cfhQAw )/
#")",1 %1(
,"1(%"%132CfhQAwP•b+%
""#%(%&o""1(&
o") %&%CfhQAwW(%%"%+%
%)3%1%3%%&,!""1%&+
% ! 1%6+%$%"
#"%)#"1CfhQAw(1# #%1
)*&%hQAw?$" )",7TDO"
1$ #1"&1(&7P$1 *
132&%&!"&1CfhQAw(1#
#%1 )*&%hQAw%&"3%&!"&
1$%
W3/
"(!%%"%&3"#
"3")"31)%%
,"1%(%&$%&V("311"(23%%
&)"0&%&$%&&1$%?†P
@•~D 1L("31"%&T2"&
1$&?†P@•b~+P•b•‡`lD
W"%/
#"%"%!%" &P•b1
"%+1!(1*%%&1%&%&P
•bU",2)#"%#"(%"%&1
$%
>","% ,
/%„_@%&$%&E1
","% ,PJ?T„ibK
J
%1"%*&D(JK
J
%
%1")"1%1TK
J
%%1"%
$%#"%)(!%1!"
W!"/
%„_@%&$%&*&1!"
#"%10&#(1TK
J
%
%1"+0+ E1!")"
"!2+%„_@%&$%&JK
J
%%1"
#"%10&#&#(1(#"%)21!%1"
L"*&U"( % "2
!"&-$1 *
I3/
1,% %1&
,"(&%!%%&$%&(*
1$*%&+2!"%((+%
$%#"%)(!%113(
113QRSA
7
‡QRSA
/("31 %1("%%&
QRSA&,"1%&"1"&%&
$%&(*1$*%&"3&
W%"%1",(/H&&&1&+!&
!%)(!%1$ %$%1T
1 )21!0&"#1, &
1%&$E#"()%%1",(+
%$%#"%)1",(F#"()%%1
",(10$!1"",%%&%&$%&?$
" )",JD
4.6 Γονιμότητα, κύηση και γαλουχία
'&")*)(%KW2%9% "&
)&U"(&)&
")*)(%,2)2)&
1$ )*)(1$%W%!(&1)&
1$ $%+"%&"#3%)(&
)%)2%1 % "%&
!"&!"#"%111(
1!&2%9%&
2%%
L "#1&)2&)&#"%12
%$%U"ˆ !"!%
$%1""1$"G($ $%#"%)%!
,"2&)&H1&3%&%&
")*)(&"1E*+%#"()%%%&$%&
" 1$"G(!%1%")%W
11"(1*")0)*%&,!""1%&F
$% % "%&2%%&
O%1&
L)* %$%"
!"01%") H!% E!% 0+
$"!%%1&%&$%&*
1$0%&) I!%1&"
% "%&)*)(&1$%
'1%
L "#1# 1%$%&
0&%&%)1%U&1&%&
$%&" 1$)&")*)(%
"&1,#1,*(#"%1(
1(1!)#*)(*),2)
%)12% % "%&1%&)2)
#" %1%#H1&E0
"%"(!%0&%)1%?$" )",TD
4.7 Επιδράσεις στην ικανότητα οδήγησης και χειρισμού
μηχανών
F$%#1"((1""%%%
()%%&#"121%#0F$%1"
"E %+*%
4.8 Ανεπιθύμητες ενέργειες
W," !)21*!21%*")0
F," !)21*!21%*")01
%#"()%% &,"&,"12"G&
%1(."%#("2!%%%&#%&
,&P2,"12"G&‰%
&))1&1%&)1(&"!9%&
,"(!)21&!21%&
")&1*!2(1&," &
)" ," */
Ελλάδα
.!&I")1&:"1 *
M)*J<7
s~P-Jm")&+W!(
=%/|TJTJ7T<KTT;
:3/|TJ-78<
>&/http://www.eof.gr
H29%",, &
=",, &%&$%&$E
1""&T!&$)*)(
1$%*&1!"($%1
1," #(1#%1!"&&3&
=",, &)%1!"1$%)
1"12+%!12&12
"!2""2"#&"
)"1'1"&*2"*10+
1"1$1**#10&*2"*
1 *1%&+%" )",
I#","1&K( #E1&1%
)*)(!21%&" &,"1 ?`wQhC@hA
~RefC+`@~CD()""&"#&?"
""++1&+ )&+1D+2"1
#"&P&?1P1"!"!%D*%+
-
3!%%+"3+"3%+3%1%,"(
")2&1"o "#,"(")
!"1$*%K1$(
H29%!21%*" *
IW!21%&W" &:"1 !*"2
"%(!&+&(1"$!1#E1&1%
#"()%%%&$%&" E7)%
#"()%%%&$%&*&1!"
)%#"()%%%&$%&11,"
#(1#%1!"&&3&I!&
,&#"%12)% 3%*
!21%*" *,"1 #%/2
#&?[KD+#&?[K*&jKD+##&?[K
*&jKD+ &?[K*&jKD+2 &
?jKD+1%)*&?1"21%!21$ %
!11D.& !%)"&#%&
1, %&+!21%&" &,"1 "!
,!" $"%&
M!"$%&/
HU7"!!21%&" &
,"1 #E1%1!"$%&
21,*1%(*%% %%&
31(&*#*, &&"&2"&&
1&1"1$ ""8
!&?1&„--+cŠ7-8+cŠ7;8-DI
!21%&" &,"1 "!%
#% 3% #%21,*1%(
*%% %%&31(&*#*
U&7/H29%*#E1*!21%*" *
,"1 ,"!%!&# $
1!"1$%
Οργανικό
σύστημα
Πολύ συχνές
Όλοι οι
βαθμοί
Συχνές
Όλοι οι
βαθμοί
Όχι συχνές
Σοβαρές και/ή
απειλητικές για
τη ζωή
(βαθμού 3-4)
ή θεωρούμενες
ιατρικώς
σχετιζόμενες
‹103&
"0
&
P ‹1*3%
"%+
•,"))
+‹1*3%
0"
H(9%+
I"1*3%+
"+
W1)+
:"))+
;
2 %
1&+'"%+
'""
+M%(
1*3%+
‹1*3%+
I
%1
p 1
(!%+
(!%
1%
!"E1
P P ‹*1
L"#&
1%
2
1,2
(1&
P I"+
W1
.12"%
"+
U"
+
"
+
O"1$"
+
‹+
W1(
1+W23%%
INRKU"1
&#"&
U"!"1$%&
L"#&
%
2
(1&
P P V"!%
L"#&
1$1
2%&
!"9%&
W"3 W, *%+
M*%
*12
$ "&
L$(%&+
V1+
L"#(%&
"3%&+
U%11(&
!"9%+
V"")"
1+
Œ#"
&
"#&
P Wo+
!9%
%
2)#%&+
U"$(
2+
!(
<
!%+
M*1%
)("1(
L"#&
"2
(1&
P ,)+
‹(!")&+‰ %+
U"!%+
L)
W,+
L"#(
1(1%&+W3+
H)(+
L"#(
""&+
L"#(
!%%&+
U","(
" !
I,!1&
"#&
P W3%1%
"2""+
.,+
."!1&
,!12
I(32%
1*1%+
L*
L"#&
0&
$"!
P P •))&+u
)&
"&
"#&
P P W!(&
%! )#%+
H%! )#%+
>#1
1"+
(
1"1")(+
W""!1+
=#"+
:$1$(
#"+
W!%110
W))&
"#&
P O"1$,$
.*$ !
!"1$*%+
V"%+
U#&+
V%+O"1(
39%+
U","(
9#"%
L"#&
2
(1&
P L2+
.3%+
](#&+
•""
U1(
1$(+
U1!0"&+
W1%+
Ž!1+
8
+
!0"
1!*"
L21
*%&
L"#&
)""
2
(1&
L ""+
61&+
p+
H1+
)&
'""(
1"")+
L%+
Ž)&%& *
(&
#0"&+
L9+
M*"1&+
•%"1+
."(
,"3%+
W%&+
."+
'"+
L,)+Ž)&
*(&
#0"&+
I,)+
(
,"+
'",)
(
"1%%+
+W1
"
L"#&
(&
*
#%,"*
P V"#"!"
1+
L"#&*
10%&
%(&
")&
•"&
L"#&
"1&
"
2
H2"1
1P
1&
"!"!
%&
.3 !%1+
W*+
."2!%1+
•%""1+
%1&+
V"#"*%
"1&+
%0&
3 !%1+
W%
"1&+
L"1+
M)#"*(
"#(+
L"#(*
2#*
:2+
L"1
&+
.3 !%1+
*%+
W"%
,*!%
&+U1
"2!%1+I%1
"0+
U",2"+
H2"1
1%(
$
L"#&
1
2
(1&
P Ž)&*
"*+
•#)+
W"!")
L)*%
"!"*%&+
I )&+
Ž)&
"0+
J
2
2
M(
19+
M(
1
L"#&
*,"0
*
","*
0
P P V","*%+
W" 2"*+
W1"+
p"+
W3%1%
"%
1&
L"#&
")*
)2
(1&
12
P P (
1"")
'&
"#&
&%&2
#"()%%&
*%+
W1
U"3+
U","
%1+
#+M%P
"
!*" )&
I%1+
" &+
'"0%&
"1(+•)%+
W3%1%
!"1"
01&
F$%!"12/
HU"!!21%&" &
,"1 #E1%#"()%%%&$%&
11," #(1#%1!"&
&3&$1&1, &
""&T!&IW!21%&W" &
:"1 "!% %%#% 3%&
?U2H#&(H#&D21,*1%9%"%#%
"%"(!%(&1) &&
1&"!1,"%"(!%
επιπροσθέτως0"%"(!%11!"
$%&("%"(!%υψηλότερη συχνότητα
3%&)" 1%1!"$%&?$
7DM%#&W!21%&W" &:"1
,"!%1%$%!"12
1,*1&W!21%&W" &:"1
,"!%1!"$%&(,"!%
1!"11,"12"G&?%
J
$$)",K(#%"%9%#"%"0
"G&D
I"1&`@~C" &"%"2# 1
1,"12"G&?#","(
!%(" !13%(3+"%
"%"(!%1QRSAD.2&1"
*%%!"1$%
U&/H29%*#E1*W!21%*W" *
:"1 ,"!%!&# $
$%!"12επιπροσθέτως0
"%"(!%11!"$%&("%"(!%
υψηλότερη συχνότητα 3%&)" 1%
1!"$%&
Οργανικό
σύστημα
Πολύ συχνές
Όλοι οι βαθμοί
Συχνές
Όλοι οι βαθμοί
‹103&
"0&
P 6"%&E*("&+
I"1*3%+
H1(
%+
‹1*3%
0"
2
(1&+
•+'"%+
|
‹1*3%+
H1&"%&
L"#&
1%2
1,2
(1&
|
I"+
|
‹+
|
W1+
|
I"&
"&+
O"1$
(12
*0+
|
.12"%
I"
L"#&
%2
(1&
P V"!%
L"#&
1$12
%&!"9%&
M*1%"3% V1+
V"1+
V1)%1+
V$1+
V")1
JJ
Œ#"&
"#&
P L"#(2+
Ž)#&
L"#&
"2
(1&
U"!%+
L!%+
U","(
" !+
U","(
!%(
" !+
L)+
,)
p"3%+
="1&+
p")+
W"%
V"!%&+
V!%
I,!1&
"#&
W3%1%
"2""
I&
L"#&+
•%",!1+
U&
,!12+I(
")+
N"%!1(
L"#&
*&
$"!
P .1$&+VG
"&
"#&
P (
1"1")(+
>#1
1"K1,"
)1
W))&
"#&
I%1 *
"+V"%+
|
.1$(
O"1$*%
639%+V%+
V"("%+
639%+:$
L"#&
2
(1&+
!0"
1!*"
U1&+
L!%
, "))
‹3)&+
:"))"))
)&+
L,*
L"#&
)""2
(1&
L%+
L9
W1"")
0"
)""2+
H1(
3*%+
'"+
L %&+
JT
'",)(
"1%%+
Ž)&1&+
L,)+
W1"")
I"!2+Ž)&
*(&
#0"&+H1(
!%+
H1(
"!%+
H1(
V!%+
(
,"
L"#&
(&*
#%,"*
P M%,)(
%(
")
L"#&
"1&
"2
W*+
L"#(*
2#*
V""*+
."!%10&
3 !%1+
*%+
p#"&
,"0&
L"#&
12
(1&
2
2
,M)
, W"!") U&
"
U&) !+
MG1+
="1&+MG(
1
L"#&*
,"0*
","*0
P W1"+
U"*G"+
p,"( !"%
"%&
1*1%+
L"
'&
"#&
&%&
2#"()%%&
U"3+
W1+
|
‹(!")&+
L3
!"1"&
:)1(
$)+
Ž)& "+
Ž)&+•)%+
O*" )&+
'"0%&
"1(+
|
U"&+
J7
W"%
#E1%1
%)#%+
W"%
#E1%1%
!%%&+
Ž)&%1
)#%&+Ž)&
%!%%&
0&+
%%%" &
&
!"0
#"10
P
M0*&
|
' !"+%#%$%W!21%&
W" &:"1 **$!10'"&1•|‘+%
#%$%W!21%&W" &:"1
$!10TP7I`@~C"!21,*1%9%"%
*%"%"(!%(&1)2"&
1&12
.1"1 %,""G&/
6#!&"!&!21%&
" & % "%&1)"(&,"&%&
$%&/
U&-H29%*" *#,"!1
$%1 %,","1
Οργανικό σύστημα Σπάνιες
Πολύ
σπάνιες
I,!1&
"#&
H*%"G2"+
"#&
"2&+"+
("
"&
"#&
(1"1")(+
.1(%QT+(
#"%"+
]""+
W))1&
L"#&
(&*
#%,"*
F( "+
#(%
J
L"#&
"1&
"2
L"1&"!%10%&
2&
H$"&"1&
" &*&
H2"1StevensPJohnson
%=3(."1(
p"%?$
L"#&*
,"0*
","*0
I3,"( "
"!(& %
, *%
U")",()1*!21%*" *
H2"1#"&P&?$" )",77D
'%%$%&JK
J
2,"&%1"%*&&
%1"&*&7 !T$1 &+
"%"(!%#%TX
*&-X**$!102"1#"&P&1&
1!"&1$%?"1$ 1&
"(!""#&
"+!"
12"!2"!""
12D
#%-TX"%"(!%&
$%&K3%&)%!"
12
"12'%%$%&K2
,"&%1"%*&&
%1"&*&7 !T$1 &+
"%"(!%#%JJX*&TX**$!10
2"1#"&P&!"121$%
M1 %7&1&11
""&*7;!0$1!"1
$%($%11,"
#(1#%1!"&&3&?#2"+
"!&+)"&"&12D3
2"1#"&P&?$!1D%0!%J--
!&?7TXD 1#"JT8%1"0q8Xi
J+J<<t+1 %"3%%&!"&1$%H&
&1& %+" *
%1&11$%&#E1&13%1
1, %&"1#"&P&(/%31%%
"3%&$%&?)"11 "D+%,!!"(%
$%&?+^BD+%31%#(%%&%&
&"0&-$1 &+%31% "%&1%&
!"?$1 &D+%31%%?1%(1D+
,2?!%D+%(,( % aŠs%
"3%?[D
L ""?$" )",77D/
F$%1" )%1, % ""&+%
#"%"%!!&
*&X
J-
=11&1 %&7&1&1
1""&*7;!0$
!"1$%3&&1&
%+" * %1&
11$%&#E1&13%11, %&
""&(/%31%%"3%&$%&
?)"11 "D+%31% "%&1%&!"
?$1 &D+%31%%?1%(1D+
,2?!%DI" * %1&
11$%&#E1&11*11, %&
""&(/%31%!"(%$%&
?+^BD%31%#(%%&%&&"0&-
$1 &
"3%?$" )",77D
.&*W!21%*W" *:"1
")" ,%&&7+
!&W!21%&
W" &:"1 1*%1""%+X
#%
1%#"(%%&$%&1!"
$1% %%&31(&*#*
, &
;&1&1"1$ 878!&?J
, %&iii, %&ii
&1&1
"!"1"12D/
"1 !+
"( "+,&! &
&&&
.), !/
.&*W!21%*W" *:"1
")" ,%&&7+
$% %
%&31(&*#*, &;&1&+%
), !#%1%#"(%%&$%&
1!"1*%
1""%+X
.%!1
F*1!&?$" )",7JD/
M %1*,&!&[-0
$1!"$%&
1 %!0
$!"1$%!"121
3%323%%%*%!21%*
" *#E1*1%
!"$!10T7
!21%*" *#E1*1%!"$"0
!21%*" *!&j-0I!&[
-0$!"1
$%3%
#%&""&"*"&&%&!"&
3&
!21%*" *)" 1&!&
j-0
J;
=11&1 %&7&1&1
1""&*7;!0$
!"1$%3&&1&
%+%31%%?1%(1D(
%1(#E1%13%1
1, %&"1#"&P& ""&11*1
1, %&"&
:2
=11&1 %&7&1&1
1""&*
7;!0$
!"1$%3&&1&
%+,2?!%D( %1
#E113%1
1, %&"1#"&P
& ""&11*11, %&
"&
W!&1,"( "?$")" ,&7J+77+
JD/
M %1*,&
!&$1!"$%&
?"!&
"&D1,"( "%"3%323%%%
*%
!21%*")0#E1*1%!"
$!10T7+)" 1&!&
1,)(
,"(")?T-X*!0#*"&,"(
")’J-<+
7X1(’J;7X1
1"’8+#D?$" )",JDW!&11"
,"(")#3%11*%&%&
?77XDTTXTJX*
!01(#*"&(,"(
")23%%*"*"*0%
!"?JX& % "*"0*2
2*DX<X!&
1(#*"&(,"(
")
4.9 Υπερδοσολογία
I%0&3&")&"1$ +
1+ ""+$)+)"""!1
1"")+(12*0F"(
10%")&""1$
%!1&!"&%"&"&
"1$ &1#%," ,)*
0%0*%"%9%!00&
5. ΦΑΡΜΑΚΟΛΟΓΙΚΕΣ ΙΔΙΟΤΗΤΕΣ
5.1 Φαρμακοδυναμικές ιδιότητες
J<
:"1!"(%)"/"
?1$%&D+*&`_/l‡-
F$%11%P"3("$1(
,!""1%+%")*&&1&
#"%)21&""1&%&"3(&P,!""%&
?P•bDF$%")1*,"*E10
*?$" )",JD=E11%
(1"(P•b+%!1(,*," %?_yzvCD+
"2&)*+ %&,)2&
2&+ #1%"&)"0&H"1E*
11#2!%!"0" 2"%
$%3")("%11
3%+%1"#E1%*%%&
" %&%&!1(&,*," %&%3%
V "#3&1$1&P•b%$(
"1E%"%1!*%&3"2
3&!132+%" E&""*%2!%
3"$G23&?@d`DF*1 *%P•b
%)%&(~d`%&"*G(&
2!%&!0&@d`~d`"%)%
"("% 3%+%"%P•b1"
%"%%1& "&!1%&%
1%""%1% 3%! "I
" &%&(&%&2!%&@d`~d`
""3%1*&2"
E#2"1$EP•b
1#2""!1
"&#&""!&"&/
M!"1$%"(!"
"#&"
L11"(+#%1%+)#1%
, %&>>>(1(!&1"#&
">>>? @ABCD%"E%#"(%%&
$%&%"(!"!01"
#&"?M%k`_+M--DH(%1(+8<;
!&#(!%)*)(1$%?JK
J
2,"&%1"%*&)J$1 &!21P
$1 #*"&, "1#"%)212&TP
$1 *)J7$1 &D(P•b$"%?H#(1
„zf/JK
J
$"%&#"%)21%&,$*&
!21%7JK
J
P•b#"%)21%#*&
,$*&?fgACD+%%*&%%%1"+ !J<%1"&
)J7$1 &DF$%( #21%
J8
11,$*P•bKl…*&"&%$*%
2!"% "*%!1?)&
%&/+8J/8XL.+<“+-DH
#%1%!1+)#%&," &%&
$%&12P•bKl…%$*%
2!"%%($*%*)&
%&+<<?8XL.+;;“++’+-<D+<-
?8XL.+;7“++’+-D+#F 1%1(
#""2!%%&%)1(%& %&(-+8#"
H1"#1%"1"( %fn+
#!%%*"%%&$%&)" 1
fgACP•bKl…I" *" )&("!"1
#1%&(& %&)1"%,!2
)1/%+#"&%#"")(1$%%
#%%+,2+a`%"3%+1,&%
"3%#0"H%"#%1%!1+%
$%30"%•bKl…)%
$*%2!"%?)&%&+<78+8XL.
+;T8P+8;-+’+JJD+!0&%&)%(
$*%?)&%&+<J<+8XL.+;P+8;+
’+JTD
O"H12""#&"
=11"(+#%1%+)#1%
(1(, %&T!&1>>>? @ABCD
"#&"+%"E%#"(%%&
$%&113?kalŠkD)%
"(!"!01"#&"?1%
dŠ-8-<DH(%1(+877!&#(!%
2&T$1 *)J7$1 &1$%?
K
J
2,"&%1"%*&)J$1 &!21%
$1 (&D113?TK
J
,$)#% "& **J*"0%%1" !T
$1 &D87J!&#(!%fgACP•b
$"%H%"*"#( %) %12!"
?@•cD%!1>==+kalŠk3
%1 0"P•bKl…?”~’+<+8XL.’q+-8++8Tt+
’+7D=@•cT%(;X)kalŠk
-;X)P•bKl…F %)"2
%%1v•c%"E 1
1”~+;<?8XL.’q+-;++8Jt+’+J7D)kalŠkP
•bKl…=kalŠk31 %*"%&*&"&%
($*%?ŠcD1”~+<;?8XL.’q+;J++t+
’+7<-D1," ETX1*%2)
! =&Šc(;<X)kalŠk
;7X)P•bKl…=#1%&$E
T
1#""("%%&81(&)Šc;1(&)
@•c="%&3&*!21%*
")0(9%"&%&!"&12
1kalŠk?JXD2)"%1&%&1!"&P
•bKl…?8XD%!1>==
M!"$%&1"!
"
L12%1#1&+"&+
#%1&)#1&, %&>>>&1&
?cŠ7-8•cŠ7;8-D+%"E%#"(%%&$%&
)!""0%&)"11(&12"!2
"?~DH&&1&+-T!&
#(!%)*)(1$%?JK
J
2
,"&%1"%*&)J$1 &!21%$1
(&#"%)21%2&T$1 *DI-7
!&#(!%)*)(1P•b$"%
?#(1„zf/JK
J
$"%&,$*&!21%
7JK
J
P•b#*&,$*&?i…fgACD%%“%
%1"+ !J<%1"&DF(1("%
2#%1%!12?3)%%
"%(D(J+;X?$%D-+;X?#(1„zfD+
j+JI 1&#"1#"%33%%&
(7%1"&?$%D77%1"&?#(1„zfD
F 1%$*%(T8J%1"&?$%DT8
%1"&?#(1„zfD."&+!1
)" 1)%1!"1$%
"!"2)"%1#(110"0%&
)"11(&
O"12)"0%&)"11(&!"
12"!2"
L11"(+#%1%+)#1%
(1%, %&>>>?pI-8--D%"E%#"(%%&
$%&113(11
3QRSA)!""0%&)"11(&
12"!2"F1%1"#J1"%/
"#1"&J0-T7!&
#(!%2,"&1 &!"&
" 1$kalŠk(•Šl•ŠkP7+!JnJ
")1"&7!&#(!%7
,"&1 &!"&+" 1$kalŠk
, "1+•Šl•ŠkP7, "1+kalŠk
QRSA+•Šl•ŠkP7QRSA];)
#(1!"&
T
U&;H#(1O"&%M%dŠ-8--?~D
Θεραπεία ∆όση έναρξης Πρόγραµµα
•Šl•ŠkP7
(
•Šl•ŠkP7
|
‡QRSA
Šngge
lARfQfh
P•gAfhfAhRg
<K
J
i…J
0"&
JK
J
i…J
0"&
7K
J
i…
fgAC+
!21%
-K
J
i…
JJ0"&
Šngge%
F1"+ !J
$1 &
lARfQfh&
F1"&J+
!J$1 &P
–AfhfAhRgi…
fgACK)#%+
!&F1"&
J+ !J
$1 &
vgRf(
‡QRSA
KBi…TP8
F1"+"
•Šl•ŠkP7+ !J
$1 &
kalŠk(
kalŠk|
‡QRSA
Šngge
Re
TK
J
i…J
0"&
K
J
1&J,"&
%1"%*&
Šngge%
F1"+ !T
$1 &
Re
1&J,"&
%1"%*&)J
$1 &
?!21%
$1
#*"&!"D
vgRf(
‡QRSA
;KBi…TP
8
F1"+"
kalŠk+ !T
$1 &
P•gAfhfAhRg/i…fgAC%1*& %gARfQfh
F1%P*"%*0"#kalŠk2)"%
1%"#•Šl•ŠkP7%(2)"%+
#!%%&$*%&#*"&33%%&
%(2)"%)1%!12!0
%!11"!%)!"?$<D=
1)%($*%2
kalŠk211•Šl•ŠkP7," 1%
($*%?$<DF2)"%kalŠk1
QRSA•Šl•ŠkP71QRSA(1
"!"1%"%( %H(%2)"%
!"&%&1 &+kalŠk1QRSA(
"1)" 1•Šl•ŠkP71QRSA,"
1%$*%#*"&33%?)&%&/++
8;+Xi/+<7P+JJDF 1%"2!%%#"*
"*"#02*%!11"!%)!"
(+%L12&1 &
TJ
"2!%%&1"1$ %&<
u+% %v•c%!"$$*
1%&)(& %&v•cŠcI)&
%&kalŠk•Šl•ŠkP7(+J71
8;+Xi/+;P77W2&!%&#
,"&) #(1#"&3)(*
*)*"2% %v•c%!"+#
$"!("%&3()%%)—1
U&<2"#1%&)% %
1%*"%&%&M%&dŠ-8--
U•u=W•m>FWpW‹VHF
Παράμετρος: Επιβίωση χωρίς Εξέλιξη της νόσου λ
Παράμετρος: Συνολική Επιβίωση
1 ΕΤΟΣ ΕΠΙΠΛΕΟΝ ΠΑΡΑΚΟΛΟΥΘΗΣΗΣ
Παράμετρος: Επιβίωση χωρίς Εξέλιξη της νόσου
Παράμετρος: Συνολική Επιβίωση
^avv’)1&%!1&!0^^i__’%!1&1
"!%)!"
H1#%1%+)#1%(1(, %&>>>
?`i~ŠD+1(!%%"%%&#"(%&$%&
"#(%K
J
)J$1 & !T$1 &
11" %)%"0%&)"11(&!"
!011"!"<J!&
#(!%0 $#(!"
?’7D+!"12?’7DF#(
!""#!""0%&)"11(&1$%
?JK
J
2,"&%1"%*&)71"&D+2"%&)"11(&
" %?TK
J
%%1"D1&
TT
$%&"%&)"11(&?K
J
2,"&%1"%*&
)7%1"&D13?TK
J
%%1"DF
!"12"#!""0%&)"11(&1
$%?K
J
2,"&%1"%*&)71"&D+
11" %?JK
J
%%1"D?kali~iD
1$%&2"%&)"11(&?K
J
2
,"&%1"%*&)7%1"&D13?TK
J
%
%1"DN2!"&#"%)(!%(1T
$1 *H%!""0%&)"11(&% 1%$*%
#*"&33%%&%!11"!%)!"
(+<1(&?8Xi+P-+J1(&D)%1!"
$%&;+<1(&?8Xi;+P<+T1(&+’+JD)
kali~iu#%13%1%*%
)""(&3%&"& % "
%&!"&"0%&)"11(&1m.li~i?J-XX)
kali~i%$%"0%&)"11(&+#D
=kali~i#)"!1P•b|" %?•Šl•i~iD
"&#%1&1&1!&11
"!"=#(1kali~i" 1$
$%K
J
2,"&%1"%*&&%1"&*&7
&2"0$1 *11" %
JK
J
%%1"H%1)2"%1%?‡iPD+
!&#(!%0 $!"(&
(1%&1•Šl•i~i?’77D+fgACP•b?i•lD?’7D(
kali~i?’7D"!*&#(!%0
1$ ,(!"1RgRfn(
, "1= 1v•c(;+-1(&)•Šl•i~i++8
1(&)i•l?’+7)%2)"%1•Šl•i~iD+<
1(&)kali~i?’+D= 1Šc(JT+1(&)
•Šl•i~i+;+-1(&)i•l?’+8D+<+81(&)
kali~i?’+J;DŠ!&$!"1kali~i
(*21) $!1)""(3%
)" 1•Šl•i~i? ""7<X7X)kali~i
•Šl•i~i+#D
H%1%aŠ~_!&#(!%0 $
!"(&(1%&1•Šl•i~i?’7D(kali~i
?’77D1"!%#%% P,(!"
1RgRfn(, "1I#" 1v•c
%&(&$*%&?ŠcD(1"")kali~i
•Šl•i~i?v•c+88+-1(&Šc7+<
8+81(&D+"!,"!%29%
""&!&$#(1kali~i?7Xkali~i+
+X•Šl•i~iD
T7
H%%11%1%&cBfreg+!&
#(!%01$ •Šl•i~i(kali~i=
(&"%&(78X&1kali~i
7<X&1•Šl•i~i?’+;-DH&%&
!"&+T;X*!0&1kali~iJ-X*
!0&1•Šl•i~i#3&%&
?’+-DF3%("1132*!"0+1
%3"%%&"&,"!%#
!&$!"1•Šl•i~i
I„feeg#"%1%1&
"&" *1&0"#1( %
*#%1*102)"%&*!"0
#%1 *1•Šl•i~ikali~i%!"~M
%1(1*%233%&%&#%
1•Šl•i~i?”~++;-+8Xi++-JP+8+vj+D+
11"%*#(#(
#(1kali~i#"%1(!%
L11#%1%(1%?cfAgBfCeg+
JJD%"•Šl•i~i|QRSA1kali~i
|QRSA3%1&,"&v•c(
Šc132*!"0I!&#(!%0
1$ •Šl•i~iQRSA?H&P`+’-;D(kali~i
QRSA?H&P‡+’--D'H&‡+#(1
1kali~i#"%1(!%$%K
J
2,"&
%1"%*&)7%1"&|" %JK
J
%%1"F
1%$*%#*"&33%%&?v•cD(+<+8
1(&+’+-7+($*%J+;J;+1(&+’+
"%&7+wT8+<X+’+TJ)•Šl•i~iP
‡Qkali~iP‡Q+#I!&$
!"1kali~i|QRSA,"1%1
9%"%*% ""&+12"%&"&
"10" *#"&P&+)" 1&
!&$!"1•Šl•i~i|QRSA+1
%1 3%1&!"(&%!"+10&*
*&%&!"&
L11"(+#%1%+)#1%
1%, %&>>?W>I˜~˜-7D%"E%#"(%%&
$%&1"#(%<K
J
)J$1 & !T
$1 &11" %QRSA)%
"0%&)"11(&!"!011"!
"J!&#(!%"%1
#(1kali~i1$%?<K
J
2,"&%1"%*&
)J$1 &!21%;(1"%"(&D+
" %?JK
J
*&)#%T %%1" !T
T
$1 &DQRSA?;+KB*&)#%T*&8
%%1" !T$1 &DJ;!&
#(!%)*)(1$%?K
J
2
,"&%1"%*&)2$1 &!21%;(1"%
"(&D+3?TK
J
*&*"%)#%%
%1" !T$1 &D+QRSA?;+KB*&
)#%T*&80%%1" !T$1 &DM
11% ""2!%%&%!12%&
1%&J-+J1%0+"&%!"(*&
" E" */
U&82"#1%&)%1%`iŠ
˜~˜
kalŠk|QRSA
?i__/d’J;D
="%1
kali~i|
QRSA?i__/
d’JD
W)
2?”Shw
hefD8Xi1(
.$*%#*"&.33%%&p -(&
i__
8Xi
;-X
-8P<7X
<7X
;;P8X
P
Y %$*%#*"&33%%&
i__
8Xi
+7(&
8+“J+
J+(&
+<“T+J
+8T
+<J“+;
v’+T
Y %($*%
i__
8Xi
J7+7(&
8+T“T+;
J+(&
J+“T+
+8
+-<“+8
v’+7
O"12)2"%&)"11(&!"
12"!2"
L11"(+#%1%+)#1%
(1(, %&>>>?pI-8-;D%"E%#"(%%&
$%&113)%!"
2"%&)"11(&12"!2"H
(%1(+-J;!&11"!
"*1# $"%)1*&!"1
T-
" %11#(1"#
–Afhfzhw*&!""0%&)"11(&#(!%
!"1kalŠk(•Šl•ŠkP7')")"11
kalŠk•Šl•ŠkP7?#*"&"!(%2
,"1 (QRSAD+;=kalŠk
#!%*&1%P0"#%1•Šl•ŠkP7
%&2!"%&$*%& "*
%!1%!11"!%)!"?$
D=1#kalŠk211
•Šl•ŠkP7," 1%($*%?$D
F 1%"2!%%#"*"*"#0
2*%!11"!%)!"(J+%
L12&1 -1(&
"2!%%&1"1$ %&
U&2"#1%&)% %
1%*"%&%&M%&dŠ-8-;
ΠΡΩΤΑΡΧΙΚΗ ΑΝΑΛΥΣΗ
XELOX
(PPP*: N=251,
ITT**: N=313)
FOLFOX-4
(PPP*: N = 252,
ITT**: N= 314)
Πληθυσ
μός
Διάμεσος Χρόνος έως το Σύμβαμα
(Ημέρες)
HR
(95% CI)
Παράμετρος: Επιβίωση Χωρίς Εξέλιξη της Νόσου
vvv
i__
7
77
-<
7-
T
?<;•
J7D
8;
?<T•
7D
Παράμετρος: Συνολική Επιβίωση
vvv
i__
T<<
T-T
7
T<J
;
?<<•
TD
T
?<;•
T;
JTD
6 ΜΗΝΕΣ ΕΠΙΠΛΕΟΝ ΠΑΡΑΚΟΛΟΥΘΗΣΗΣ
Πληθυσ
μός
Διάμεσος Χρόνος έως το Σύμβαμα
(Ημέρες)
HR
(95% CI)
Παράμετρος: Επιβίωση Χωρίς Εξέλιξη της Νόσου
vvv
i__
7
7T
--
7-
7
?<;•
J7D
8;
?<T•
7D
Παράμετρος: Συνολική Επιβίωση
vvv
i__
T8T
T-T
7J
T<J
?<<•
J;D
J
?<-•
JD
^vvv’%!1& "*•^^i__’%!1&1"!%
)!"
U"#*"%1&)"&"&/
L11"(+#%1%+)#1%
(1(, %&>>>!&1"#*"%1)"
"%"E%#"()%%%&$%&)%
!""0%&)"11(&"#*"%1)"2"
?„l;TJDH—(%1(+-!&#(!%
)*)(1$%?K
J
2,"&%1"%*&)J
$1 &!21%;(1"%(D%
?<K
J
1,$)#% "&J*"0 !T
$1 &DH -!&#(!%)*)(1
P•b?<K
J
%1"%*&+1#(,$)#%&
%1"&*& !T$1 &D%?<K
J
1
,$)#% "&J*"0%%1"+ !T
$1 &DF$%11%(
0"12P•b1%#"&
T<
%$*%#*"&33%%&% "*
%?)&%&<•8Xi-TP7DF
1%1(%&$*%&#*"&33%%&(+-
1(&?$%|%D+1%0?P•b|
%DI)&2)% "%&$*%&
?($*%D("1&1)2)%
$*%#*"&33%%&?)&%&<•
8Xi-7PTDF 1%1(%&$*%&(+1(&
?$%|%D8+T1%0?P•b|
%D
L11#%1%"(+1%, %&>>>+
%)"!%%$%1P•b
3%&!&1"#*"%1
)""+%"E%#"(%%&$%&)
%!""0%&)"11(&"#*"%1)"2
"?~a`lPJDH†(%1(+J!&
#(!%1"1"#1JxJ
!7#%%&1%&/
Pa•/hAR?K
J
fgAC%%%1" !T$1 &D+
RCge?-K
J
*&J*"%)#%%%%1" !T
$1 &DP•b?JK
J
%1"%*&#"%)211
#()#%1*"(&)"11(&D
Pam/hAR?K
J
fgAC%%%1" !T$1 &D+
RCge?-K
J
*&J*"%)#%%%%1" !T
$1 &D$%?-JK
J
2,"&%1"%*&
#0&D
PaI•/hAR?K
J
fgAC%%%1" !T$1 &D+
3?TK
J
*&J*"%)#%%%%1" !T
$1 &DP•b?JK
J
%1"%*&#"%)211
#()#%1*"(&)"11(&D
PaŠm/hAR?K
J
fgAC%%%1" !T$1 &D+
3?TK
J
*&J*"%)#%%%%1" !T
$1 &D$%?-JK
J
2,"&%1"%*&
#0&D
F %*"*)0"1"*1%&
"*%!131%P*"%%&
(&$*%&*#%1 **$1*%
$%*$1*P•b?)&
%&+<-L.8X/+<P+88D)$1
%3#(1$1%%
?)&%&+8JL.8X/+<P+DF 1%1(
%&(&$*%&(+81(&"#
$%#(18+-1(&"#P•bF
T8
1%1(%&(&$*%&(+1(&
"#%#(1+71(&"#
3
F$%#%&#"%1%!11
3)%!""#*"%1)"2
"M&11!"$%&2
%$%1,E""#*"%1
)""
"&#&"+"!&"#*"%1&
)"&/1P %
M1 %-010?1&cŠ7-8+cŠ7;8-+
„--+dŠ-8--+dŠ-8-;+„;TJD%"E%#"(%
%&$%&% %P•b1!"
!"12)"""F31(
*1*1"1$ T8;!&$)*)(
1#(1"#$%T;7!&
$)*)(1#(1"#P•b” 1%
($*%(;T1"&?8Xi/-;•;7D!&
$)*)(1#(1"#$%
-<T1"&?8Xi/-7-•;D!&$)*)(1
#(1"#P•bI)&%&)%
($*%(+87?8Xi/+<8•++’+7<8D
""E&#(1"#$%
0"#(1"#P•b
"&12/
O"121$%3%
"#*"%1(1"12
L11"(+#%1%+)#1%
(1(, %&>>>%"E%#"(%%&
$%&113%+)%!"
!01 "#*"%1(1"12
#&"3(&#%1!"&+
1"1$1%&1&!"%&H—(%1(+J
!&#(!%)*)(1$%?JK
J
2,"&%1"%*&)J$1 &!21%
$1 (&3%;K
J
1,$
)#% "&0"& !T$1 &DJ-!&
#(!%1!"13%?K
J
1
,$)#% "&0"& !T$1 &DF
$*%"#&12$%|
3%&?’+J-DF 1%1(%&$*%&(77J
%1"&?$%|3%DTJ%1"0
?1!"13%DF "%"21%
"%2#%1%!12
7
?3)%%"%(D+(7+-X?$%|3%D
J8+;X?1!"3%&D/’+<I#"&
1#"%33%%&"#&12
$%|3%&?j+D
F 1%1(#"1#"%33%%&(<-
%1"&?$%|3%DJ<%1"0
?1!"13%D
M!"1$%#&30+
#%1!"&"#!"%)%%
!"1!"%
L12
"&&1&, %&ii%"E%#"(%
%&
1!"&$%&!&#&
30#%1!"2
#(1&"#
!"%(!&)&&
""*
!"1!"%H†&&1&JT-
!&$)*)(1
$%?JK
J
2,"&%1"%*&)J$1 &!21%
$1
(&DF "%"21%1(
"%?3)%%"%(D(JX
?"0%1(D
JX?2"%1(DŠ 1&#"&1#"%33%%&
(8T
8<%1"&F 1%$*%(T<7
T;T%1"&
N&3&/
M1 %7&1&11
""&*7;!0$1!"1
$%($%11,"
#(1#%1!"&&3&?#2"+
"!&+)"&"&12D3
!&!"1$%(*
2"1#"&P&?”•cD#1)2"%(
$*%)" 1&!&(*”•c/
1%($*%1"&?8Xi;+JD
-81"&?8Xi-T<+;7D1)%&+-?8X
i+-++--D
U"&%!1&/
I."*G&I")1&:"1 *#0)(
%#"*%$(&*1 **101
$%&&%)"&"2
%!121"*1#&""!2+
)""*1"12?$
" )",7J)%","&# 1%"(
#"(%D
7
5.2 Φαρμακοκινητικές ιδιότητες
F,"1%(%&$%)%!2"&
*JPT7K
J
K%1"I" 1"%&
$%&+%&P3PP,!"%&?†P@•~D%&
P3PP,!""%&?†P@•b~D1"(!%&%1"&
7("1&F`bP•b(TPTX9%"%
%7%%1"M*%%&%&%&$%&10%
%1(!%P•b"") %&
%&)*%&1%P)"11(&,"1%(&"2
1$%
W"",%%
M %1&#"()%%+%$%"",
#*&0&+1!%1%1"(&
1$&+ˆP@•~ˆP@•b~F#"()%%1",(
0"!1%&"",%%&%&$%& #
*&11 1"%%, %&
"#(& *%12%)"*%&P#"?`bD%&
ˆP@•b~%&`b")11$%P•bM
#"()%%%&%&JK
J
%7%%1"1#"()%%
1 %(9%",(&+",&)"0& 1
?n1KgD)%$%+—P@•~+P@•b~+
P•b•‡`l(7-;+T+J+87-#
I#"&3%&*",*)"0* 1
?_n0"&D(+J+J+JTT7I1&`b
P™
1šyKg(;;+;J7+J7-+JTT-T
1(
iQehf1&!"0 1""%
$%+ˆP@•~+ˆP@•b~P•b
7X+X+-JXX1"*ƒ&+"*&1%
*1%
]1#%11&
F$%1$E"# %%(
"$3" %ˆP@•~+%%#
1"ˆ“@•b~%(1 %+
$""*&("&12&2&
U""*(")%%%&ˆP@•b~"%"
%#+%!1(,*," %?_yzvCD=
E111#%(")%%
"2&)* %&)&2&
(!*%"F%#%&
E1(&$)(&1"(&%&$%&P•b
%)9%"&)"0&&*10
0H%"*%*)*#&"+%")*)(P
7J
•b1,EE 2")%"
2"*)*M %1&#"()%%%&
$%&!&1)#&"+)&
%&)"*%&P•b)&#&""&
)2&2&(T+J?1 !%+8<+DI)&
%&)"*%&P•b)"& 1(J+7
?1 !%T+88+8’<D+0)&%&)"*(&
)&2&"& 1(<+8?1 !%T+
J+<+’<DF" %%&!1(&,*," %&1"(!%
$"!%7,"&1)2"%"*!()#&
"),)H21,*1
G#%1&1&+%,*," %%&!1%&
1,EE 2")%"
" 2"
FP•b$E""*E1o") %%&
""1%&?@v@D%2)"3("PP
,!""%?•b”JD”""1 %
2"1%&P,!"P"G"32?•bv`D
= +%$P"GP" % •bv`P,!"P$P
%?•‡`lD%$ 12"F" %%&
o") %&%&""1%&?@v@D
""12%%&$12W "%&@v@
1"%)(3%1%3%%&$%&
?$" )",&7T77D
W$(
I#"&%1E*(&%&$(&?e
KJ
0"&D%&$%&+
†P@•~+†P@•b~+P•b•‡`l(<+
+--+;-TJT#F$%
1$&%&1"2"*&1$(2"
U8+X%&#"%)21%&%&%&$%&
2"F"%*" *
1%?J+-XDI2"&1$%&"2"
•‡`l+"*2;X%&#"%)21%&
%&U"TX%&#"%)21%&%&"
2"*&1 $%, "1
O"12
M&, %&>11%3)%%%&"%&%&
$%&%,"1%(%&3%&
%&3%&",+31"%%&
$%&%,"1%(%&3%&(
3%&?n`bD1"%%&
3%&(%&3%&%,"1%(†“
@•b~
7T
:"1%(2&%!12&
L")(!%,"1%( %%!12!0
1"!")*)(&1$%
$%JK
J
2,"&%%1"=)&+%
"(%(&1 %&"%"3%%&
)*)(&+%& ˜hfrCBz?˜hfrCBz
vhrfhRceeACD+%(#"!"%+%*1%"2+%
`c`_`l`_#1 %1("%
%,"1%(*†P@•b~+P•b•‡`l
W!&1%( ")*%01 */
21,*11,"1%(1%+"!&1
(*&1"%(")+)*%0
1 *+%$!1%%&$%&%!%
%P•b1"3%!2)" 1&*!0
#*"&%(")L "#,"1%
1)!&1$"(%( "
W!&1,"( "/
1$ %1,"1%(
1%"!&!&1(*&$"(,"(
"+ "#13%)"%%& !"%&
%&"%&%,"1%(1 $%,"1
%&P•b]"!%% !"%%&"%&%" E%
%1(!%%—P@•b~?TX23%%%&`b%
!"%%&"%&10 XD%•‡`l
?7X23%%%`b% !"%%&"%&
10 XDI•‡`l&1$%&#*"&
1*("%"%
F*1/
1$ %%,"1%( %%!12+
&" 1$!&11) 2"&%0?J;1#"
<-0D" 1$JT7?7-XD!&%&
1)2"%&(%&*-0+%%#1"%
%,"1%(†P@•b~P•bF`b•‡`l
3(!%1%%?JX23%%%&%&#*&
1X23%%%`b•‡`lDW(%23%%
,!1$(%&,"(&")&
:" )&
/1&#"()%%&<J
K
J
$%2,"&%1"%*&)7%1"&+
> *&!&?’<D#" T-X#1%"%
n J7X#1%"%`b)%$%
+ !&?’JJDI> *&!&%&+
#" JX#1%"%n T7X
#1%"%`b)%•‡`l+ !&F
(%10*,"0 )*%L
%10!%%1&,"& %!% &
1$&?›P@•~+›P@•b~P•bD
77
5.3 Προκλινικά δεδομένα για την ασφάλεια
H1&3%&%11**+%1"(
1&#"()%%$%&!(&RzffgAC
" 3&" &)""+
1,1%2%1+&*
,!""10W&3&" &+(
"91&U"%"(!%"1(3%
#"%"E1%,&K"1&)&+1%
$%F$%"2%(&3%&
3%&"2"2(1&
"))(3%?#" %%1 *v~P
{_PD(#21%!(&1 ,$#"()%%
?KBD #1 %11&1&
#"%)21&&?T;8K
J
%%1"D
M1%")%&J012&"#1
3%")%&%&$%&
% "!"*1*10)1%&+
"%"(!%$ $%%)1%!%00
$$%U" +(%"%(
"91%1 1"#*"&%(9%,"1
."!*&+ % "%&T%&$1 &%&1%&+
1,%",&,&1$&
")*) ")"00u+
,1("911 1"#*"&%(9%
,"1 ?$" )",7-D
H1&1$"3%&")%&+
"%"(!%3"01&3(&%1$"G(
"",%%")%H&!(&+"%"(!%
$(1$"G(!%1%9%&&+
("#13%")%&
F$%(13)&$("
?1`CD(2"!%0?1)(&
1 3%&…;8K”v~_EyCehDQehfU"ˆ
+"1*&1 )?%P•bD+%
$%()!"01,2"
?QehfD1,%1!( %1&
RhfARgAC1*00?QQfD
6. ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ
6.1 Κατάλογος εκδόχων
7
U"(&/
p"2#&""1E%+
M""("%+
V"1E%+
Ž"&3"+
HM)(
. 9%/
V"1E%+
L3?.;D+
= %&+
U!)%7
3("?.;JD+
"3("?.;JD+
6.2 Ασυμβατότητες
L,"1E
6.3 Διάρκεια ζωής
T#"
6.4 Ιδιαίτερες προφυλάξεις κατά την φύλαξη του
προϊόντος
M%, !"1"1)2"%*T
f
6.5 Φύση και συστατικά του περιέκτη
Aluminium“PVCKPVDCAluminiumPPVCPPEPPVDCblisters
/-
/J
6.6 Ιδιαίτερες προφυλάξεις απόρριψης
!1%#"%1%1"G(""9%&!"
""21,*1%#21!
7. ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ
W•F=FΑ.Ε
7-
‹=ƒJ+
T-;;W#"&W(&
=%/J<J-
Φαξ: 210 6207503
8. ΑΡΙΘΜΟΣ(ΟΙ) ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ
9. ΗΜΕΡΟΜΗΝΙΑ ΠΡΩΤΗΣ ΕΓΚΡΙΣΗΣ / ΑΝΑΝΕΩΣΗΣ ΤΗΣ
ΑΔΕΙΑΣ
10. ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ
7;
